Adverum Biotechnologies Announces 3-Year Efficacy and : vima

- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of...

Related Keywords

United Kingdom , California , United States , San Francisco , American , Carl Regillo , Laurent Fischer , Carld Regillo , Adverum Biotechnologies Inc , Exchange Commission , Clinical Program Milestones , Healthcare Products Regulatory Agency , Retina Service At Wills Eye Hospital , Drug Administration , American Academy Of Ophthalmology , European Medicines Agency , Nasdaq , Retina Subspecialty Day , American Academy , Extension Data , Gene Therapy , Preliminary Data , Year Results From , Protein Data Highlights , Baseline Characteristics , Clinical Program , Program Milestones , Retina Service , Wills Eye Hospital , Fast Track , Innovation Passport , Private Securities Litigation Reform Act , Quarterly Report , Nasdaq Advm , Adverum Biotechnologies , Nc , Wet Macular Degeneration ,